Intellectual disability and cerebellar atrophy occur together in a large number of genetic conditions and are frequently associated with microcephaly and/or epilepsy. Here we report the identification of causal mutations in Sorting Nexin 14 (SNX14) found in seven affected individuals from three unrelated consanguineous families who presented with recessively inherited moderate-severe intellectual disability, cerebellar ataxia, early-onset cerebellar atrophy, sensorineural hearing loss, and the distinctive association of progressively coarsening facial features, relative macrocephaly, and the absence of seizures. We used homozygosity mapping and whole-exome sequencing to identify a homozygous nonsense mutation and an in-frame multiexon deletion in two families. A homozygous splice site mutation was identified by Sanger sequencing of SNX14 in a third family, selected purely by phenotypic similarity. This discovery confirms that these characteristic features represent a distinct and recognizable syndrome. SNX14 encodes a cellular protein containing Phox (PX) and regulator of G protein signaling (RGS) domains. Weighted gene coexpression network analysis predicts that SNX14 is highly coexpressed with genes involved in cellular protein metabolism and vesicle-mediated transport. All three mutations either directly affected the PX domain or diminished SNX14 levels, implicating a loss of normal cellular function. This manifested as increased cytoplasmic vacuolation as observed in cultured fibroblasts. Our findings indicate an essential role for SNX14 in neural development and function, particularly in development and maturation of the cerebellum.
Intellectual disability (ID) syndromes with a small cerebellum constitute a clinically and genetically heterogeneous group of neurological disorders for which the underlying molecular etiology is diverse and established in only a small subset. Several different cellular mechanisms have been implicated including mutations in SIL1, coding for an endoplasmic reticulum resident cochaperone, which cause Marinesco-Sjogren syndrome (MSS [MIM 248800]); 1 sialic acid disorders such as Salla disease (MIM 604369); 2 disorders of peroxisome biogenesis in atypical Refsum disease (MIM 614879); 3 congenital disorders of glycosylation, especially type 1a caused by mutations in PMM2 (MIM 212065); 4 and the X-linked ID-small cerebellum syndrome caused by mutations in OPHN1 (MIM 300486), a RhoGTPase-activating protein (GAP). 5 Related phenotypes include the group designated as pontocerebellar hypoplasias, 6 within which causal mutations have been found in a number of genes involved in tRNA biogenesis (including RARS2 11, 12 and another (CHMP1A [MIM 614961]), with a dual role in protein sorting at the endosome and chromatin modification at the nucleus. 13 Other cellular processes include synaptic and cell junction function (CASK [MIM 300749]), 14 cell cycle progression, and cell division (the serine-threonine kinase VRK1 [MIM 607596]). 15 At the biochemical level, it is not clear how disruption of many of these genes leads to hindbrain hypoplasia or atrophy. The classification and diagnostic approach of cerebellar disease associated with ID in childhood is complex and challenging, often depending on the careful identification and assessment of neuroradiological and other clinical findings.
We recently described an autosomal-recessive condition in a consanguineous Portuguese family (family 1) in which two sisters (Figures 1 and 2A) share a similar phenotype, characterized by severe cerebellar ataxia, severe intellectual disability (ID), absent speech, coarse facial features, relative macrocephaly, brachycamptodactyly of fifth fingers, and early-onset cerebellar atrophy (Table 1) . 21 To perform genetic analysis aimed at identifying the causal mutation, informed consents were obtained for all of the parents, probands, and siblings according to protocols approved by the ethical review committees at Great Ormond Street Hospital and Coimbra Hospital Centre. Specific parental consent was also given for the use of all of the clinical data and facial photographs included in this manuscript. The family was . Notice the similar facial features mainly characterized by broad face, fullness of the upper eyelid, broad nasal base and slight underdevelopment of the alae, broad and long philtrum, thick lower lip vermillion, and fifth finger brachycamptodactyly. In the first years of life, no neuroradiological anomalies were observed in affected individuals, as depicted here by the normal T1-weighted mid-sagittal (L) and coronal (L 0 ) MRI sections, which have not yet been repeated for this individual. MRI images performed for other individuals during infancy are unavailable but were reported to be normal. At older ages, affected individuals have a small cerebellum with thin folia and enlarged fissures, suggestive of global cerebellar atrophy as shown here in the T1-weighted MRI images from three of the children, one from each family (mid-sagittal sections I-K; coronal sections I 0 -K 0 ). The pons appear small but in comparison are well preserved.
then investigated by first delineating regions of shared homozygosity followed by whole-exome sequencing to identify variants in the implicated regions. Homozygosity mapping was performed on the two parents (III.1 and III.2), two affected siblings (IV.3 and IV.6), and four unaffected siblings (IV.1, IV.4, IV.5, and IV.7) using the Infinium HD HumanCytoSNP-12 BeadChip (Illumina). This revealed 20 candidate regions spanning a total of 35,846,704 bp, which contained 450 RefSeq and 886 UCSC transcripts (Table S1 available online). Haplotype analysis of the SNP data defined the largest homozygous region of~18 Mb on 6q13-q14 (hg19; chr6: 70,500,118-88,497,536). Exome sequencing of the proband (IV.3) from family 1 was performed using Agilent SureSelect v.4 and Illumina TruSeq. Enriched libraries were (B) Sequence traces for families 1 and 3 show point mutations in genomic DNA (top trace, mutant; bottom trace, wild-type). For family 2, the sequence trace spans the deletion breakpoint, in genomic DNA, and indicates the location of the breakpoints within two Alu repeats in the schematic diagram of the SNX14 locus shown in (C) (see also Figure S1 for further details). (C) Schematic representation of part of the SNX14 genomic locus (top) and the SNX14 protein (bottom) indicating the location and effect of the mutations detected in the three families. The protein consists of two predicted transmembrane domains (TM) at the N terminus, followed by the PXA domain, RGS domain, conserved PX phosphoinositide binding domain, and PXC domain situated toward the C terminus. The deletion in family 2 is predicted to remove the RGS and PX domains, whereas the splice site mutation in family 3 removes part of the PX domain. 
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Short and broad finger/toes Figure 2C ). The c.2596C>T mutation was identified within an exon that codes for both transcripts (exon 26, based on the longer transcript) and was predicted to result in a protein truncation that would either remove the last 81 amino acids, including part of the PXC domain or, alternatively, trigger nonsense-mediated decay ( Figure 2C ). We identified a Turkish consanguineous family (family 2) with four affected individuals sharing similar clinical features to family 1 ( Table 1 ; Figures 1 and 2A ). SNP genotyping (as above), revealed 11 regions of homozygosity shared between all three of the affected individuals available at the time of mapping (IV.1, IV.2, and V.1), with the largest (8,056,114 bp) including the interval containing SNX14 in 6q14.3, being the only autozygous region in common with family 1 (Table S1 ). Individual V.1 underwent exome sequencing at Dasman Diabetes Institute (Kuwait City, Kuwait) using methodologies as described for family 1, with 89% of target bases covered at least 13 with an average depth of 333 per base. Using the same filtering parameters as those for family 1, we were able to reduce the number of variants from 199,920 to 18 (Table  S2 ). As examination of these failed to identify any of these within the regions of shared homozygosity, we decided to look in more detail at SNX14. Specifically, we viewed the reads across SNX14 using Integrative Genomics Viewer (IGV) software (Broad Institute), 24 which revealed a homozygous deletion of 9 consecutive exons from exon 13 to 21 (with respect to isoform a) ( Figure S1A and Table S4 ), while all DNAs sequenced at the same time from unaffected subjects had good read depth for this interval ( Figure S1A ). The deletion was confirmed, first noting the lack of PCR amplification of individual exons from genomic DNAs, then by testing a series of primers flanking the approximate breakpoint position ( Figure S1B ). The latter strategy allowed determination of the precise sequence of the junction fragment. The deletion most likely occurred as a consequence of illegitimate recombination between two Alurepeat sequences found in intron 12 and intron 21. This resulted in a deletion spanning 25,640 bases, described as c.1108þ1181_2108À2342del with reference to isoform a cDNA or hg19 coordinates chr6: 86,255,692-86,230,052 ( Figure S1C ). In addition, Affymetrix CytoScan 750K array analysis of the youngest affected individual (V.2) revealed a 
Abbreviations and symbols are as follows: þ, positive; À, negative/normal; U, data unknown; P, progressive: i.e., two or more sequential scans showed development/progression of the cerebellar atrophy; SN, sensorineural, moderate-severe, bilateral; NA, not applicable. a Growth measurements: For the Turkish individuals, the charts used for head circumference measurements were described by Evereklioglu et al. 19 and Elmali et al.
homozygous deletion spanning five consecutive probes within SNX14, corresponding to the interval described above ( Figure S2 ). Sanger sequencing of cDNA synthesized from fibroblast mRNA (V.1) confirmed that there was in-frame splicing between exon 12 and exon 22 ( Figure S1D ), which is predicted to remove 334 amino acids (p.Val369_Leu702del) from the full-length protein, including the entire RGS and PX domains ( Figure 2C ). We genotyped all of the available family members using a PCR-based approach to confirm segregation of the deletion. This revealed that only the four affected individuals were homozygous for the deletion, although eight unaffected individuals were heterozygous and three were homozygous for the reference allele ( Figure 2A) .
We next searched the Great Ormond Street Hospital Clinical Genetics records to identify affected individuals based solely on similar features. We performed text searches of the electronic medical records of all children known to the Clinical Genetics department using the terms ''pontocerebellar hypoplasia,'' ''cerebellar hypoplasia,'' OR ''cerebellar atrophy'' AND ''hearing loss'' and manually examined all sets of notes and clinical photographs, excluding all affected individuals with an alternative diagnosis or with microcephaly. This strategy identified family 2 (above) and a single further individual in an unrelated Turkish consanguineous family (family 3) among more than 50 case subjects matching the pontocerebellar or cerebellar search terms. The individual III.1 from family 3 ( Figure 2A ) had cerebellar ataxia, sensorineural hearing loss, slightly coarse facial features, relative macrocephaly, and bilateral fifth finger camptodactyly but generally had milder features than the other affected individuals in terms of the radiological degree of cerebellar atrophy and her motor, intellectual, and speech development (Table 1). Sanger sequencing of SNX14 exons and exon-intron boundaries in III.1 identified a homozygous canonical splice site mutation (c.1894þ1G>A), which was heterozygous in both parents (Figure 2A ). Using mRNA isolated from peripheral blood lymphocytes, we confirmed inframe splicing of exon 18 to exon 20 (isoform a), completely skipping exon 19 ( Figure S3 ). This was predicted to result in the deletion of 30 amino acids (p.Ala603_Gly632del) from within the PX domain ( Figure 2C) .
Using fibroblast cDNA, we compared mutant and wildtype transcript levels using quantitative RT-PCR with Power SYBR green PCR Master Mix on StepOnePlus RealTime PCR Systems (Life Technologies). Compared to controls, we noted significantly reduced levels of expression in families 1 and 3, whereas levels in family 2 were similar ( Figure 3 ). To investigate protein levels, SNX14 was analyzed by immunoblotting ( Figure S4 ). A single band of~110 kDa was reproducibly obtained in control fibroblasts, but no band was detected in either family 1:IV.6 or 2:V.1. For family 1:IV.6, only a low level of mRNA was present, and this may produce an unstable or subdetectable level of protein. This also ties in with the possibility of activation of the nonsense-mediated decay pathway. For family 2:V.1, the deletion removes 112 of the 131 amino acid peptides used to raise the anti-SNX14 antibody. Therefore, it is conceivable that a truncated protein is present but not detectable with this assay. For family 3:III.2, a protein of slightly lower molecular weight (~107 kDa) is detected, approximating to the loss of amino acids due to skipping of exon 19. Collectively, the mutation data are supportive of a loss of normal biological function for SNX14.
Therefore, we identified a total of seven affected individuals from three unrelated families who share a distinct rare syndrome resulting from SNX14 mutations. Neither point mutation was present in the NHLBI-ESP-EVS 4,870 exomes or in our internal database of 358 exomes. further two with duplications that encompass SNX14 and other nearby genes. Of these, only the two unrelated individuals described by Wentzel et al., 31 who have large interstitial deletions (8.7 Mb and 4.5 Mb) containing SNX14 and three neighboring genes, have some phenotypic similarity to our affected individuals. In particular this includes the presence of ID, similar facial dysmorphic features, hearing loss, and macrocephaly. Additionally, one of these individuals had camptodactyly and limited movement of the elbows. None of them were reported to have cerebellar atrophy or ataxia, but both of them had walking difficulties and one was reported to have dyspraxia. Currently, we cannot exclude the presence of a second, SNX14-specific point mutation on the non-CNV-carrying chromosome in these cases.
In an attempt to further extend the phenotypic spectrum associated with SNX14 mutations, we investigated whole-exome sequencing data obtained for a series of 36 individuals with idiopathic pontocerebellar hypoplasia, and 168 from dominant and recessive families with idiopathic cerebellar ataxia, of which 138 were recessive/early onset or no family history. However, no likely causal variants or CNVs affecting SNX14 were identified. These data suggest that autosomal-recessive SNX14 mutations are associated with a narrow clinical spectrum. The presence of coarse faces and the absence of microcephaly and epilepsy are distinctive features within this group of conditions, confirming our findings reported in the description of the first family. 21 Additionally, sensorineural hearing loss and camptodactyly of fifth fingers seem also to be prevalent (Table 1 ). Nevertheless, it should be noted that clinical recognition is challenging in infants because dysmorphic features, cerebellar involvement, ID, speech impairment, and ataxia are progressive and absent at an early age. Neuroradiological scans performed in the first years of life appeared normal but later were characterized by a globally small cerebellum (Table 1, Figure 1 ). Both the hemispheres and vermis are affected and there is separation of the folia indicating atrophy rather than hypoplasia ( Figure 1 ). Evidence for slight pontine thinning was seen in older patients. This phenotype is significantly different from the pontocerebellar hypoplasias group of conditions, which are usually more severe, with prenatalonset hypoplasia/atrophy of cerebellum and pons, associated with progressive microcephaly and seizures. SNX14 is a member of the large family of sorting nexin proteins but it has only recently been investigated for its tissue distribution and cellular function. The earliest report describes Snx14 mRNA expression using an in vitro motoneuron selection method. 33 Mice in this study were found to have the highest levels of Snx14 mRNA expression at E12.5, restricted to neuronal lineages such as the spinal cord. Expression in the brain was seen in the ventral ventricular region, the floor plate, V (trigeminal) and VIII (vestibulocochlear) cranial ganglia, the saccule of the inner ear, the developing pituitary gland, and eye. In general, mRNA distribution was described as colocalizing with Islet-1 expression, including Islet-1-positive motoneurons. 33 Furthermore, Northern blot analysis in different adult mouse tissues revealed Snx14 expression in cerebellum and hippocampus and at much lower levels in cortex, muscle, liver, lung, and heart. 33 We investigated SNX14 mRNA expression in human fetal tissue using RT-PCR and found it to be ubiquitously present in all tissues analyzed, including heart, skin, brain, kidney, bone, liver, eye, and placenta ( Figure S5 ). The Allen Brain Atlas reports in situ hybridization for the p56 mouse brain, where the highest levels of Snx14 expression were found in the granule and Purkinje cell layers of the cerebellar cortex but also in the hippocampus (granule layers and dentate gyrus) and the piriform. This was supported by data from both the human UK Brain Expression Consortium (UKBEC) and the Human Brain Transcriptome database. 34, 35 SNX14 is expressed in all brain regions, with generally increasing levels during prenatal development and then plateauing. Interestingly, the pattern the cerebellum is the region where SNX14 is most highly expressed and transcript levels continue to increase through postnatal life until adult (UKBEC data, Figure S6 ). Most recently, Huang et al. 36 described mouse SNX14 levels as being high in brain, testis, and lung, similarly showing an increase in cerebellar levels from embryonic to postnatal stages (E16.5-p63). Despite a broadly distributed spatiotemporal pattern, which might suggest function in many tissues, high levels in the central nervous system and particularly cerebellum correspond to the described phenotype (with internal organs spared), particularly the cerebellar atrophy seen in affected individuals from all three families presented here.
To date there are 49 mammalian proteins known to contain a PX domain and the majority of these are classified as sorting nexin proteins. 37 The PX domain binds to phosphoinositides (PtdIns3P) on the cytoplasmic leaflets of various organelles and it defines both subcellular localization and function of different PX domain-containing proteins including endosomal sorting and trafficking. 37 Mutations in the p47 phox subunit of NADPH oxidase are known to cause autosomal-recessive chronic granulomatous disease (MIM 233700), 38 whereas SNX27 has been indirectly linked to synaptic dysfunction in Down syndrome through impaired transcriptional regulation, 39 and recently SNX10 mutations have been demonstrated to cause a nonsyndromic autosomal-recessive form of osteopetrosis (MIM 615085), an osteoclast-related bone disease. 40 Based on predicted domain structure, SNX14 is classified within the PXA-RGS-PX-PXC subfamily along with SNX13, SNX19, and SNX25. 41 Like SNX13, SNX14 also contains a putative double transmembrane domain including a short cytoplasmic leader sequence and an RGS domain, implying they share a similar function ( Figure 2C ). The RGS domain of SNX13 can bind to and increase the GTPase activity of the G-alpha s (Ga s ) subunit of G-protein coupled receptors (GPCRs). Mediated by the PX
The American Journal of Human Genetics 95, 611-621, November 6, 2014 617 domain, this activity can occur at the endosome, allowing Ga s signal attenuation at the interface with this protein sorting and degradation pathway. 42, 43 Loss of functional SNX13 in the mouse resulted in dramatically altered endocytic/lysosomal compartmentalization in visceral yolk sac endoderm, with abnormal localization of several endocytic markers and with the appearance of abundant autophagic vacuoles. 44 A role for SNX14 in endosomal sorting and the regulation of protein degradation is supported by recent analyses of the prenatal human brain transcriptome. 45 Weighted gene coexpression network analysis (WGCNA) was used to group genes expressed within mid-fetal human neocortex into modules in an unsupervised manner. 46 This approach is extremely useful in identifying modules of biologically related genes that are not just coexpressed, but coregulated. 47 This method was applied to predict that SNX14 is highly coexpressed within a module (C25, black), 45 which is significantly enriched for genes involved in cellular protein metabolism (Gene ontology term GO:0044267~cellular protein metabolic process, Bonferroni-corrected p value ¼ 9.18 3 10 À5 ) and vesicle-mediated transport between the ER and Golgi (GO:0006888~ER to Golgi vesicle-mediated transport, Bonferroni-corrected p value ¼ 7.59 3 10 À4 ).
This prompted us to examine cellular ultrastructural morphology in skin biopsy material and fibroblast cell lines, using a JEOL 1400 transmission electron microscope (Figure 4 ). Compared to control samples, the skin biopsy showed an adequate epithelial layer with a moderate degree of hyperkeratosis and occasional apoptotic bodies.
Vacuoles with fine nonspecific granular material were identified in keratinocytes ( Figure 4B ). In the dermis, collagen and elastic tissue had a normal appearance and distribution. Fibroblasts demonstrated infrequent vacuoles with granular material and rare electron-dense laminated inclusions suggestive of lipid degeneration. No sweat glands were available for assessment and small myelinated and unmyelinated nerves were unremarkable. Next, we investigated ultrathin sections from cultured skin fibroblasts from one affected individual from each of the three families and control subjects. Affected fibroblasts were found to have frequent cytoplasmic vacuolation with electron-dense material of variable morphology including some with evidence of lamella structure as seen in multilamellar bodies (Figures 4D-4F ). Interestingly, a proportion of fibroblasts from affected individuals but not control subjects immunostain positive for p62 in a granular pattern (Figure S7 ), which might suggest a defect in the autophagy pathway, as seen in many neurodegenerative and neurodevelopmental disorders. 48 Interestingly, cultured fibroblasts from individuals with MSS similarly contain numerous cytoplasmic electron-dense, sometimes multilamellar inclusion, bodies in both individuals with and without SIL1 mutations. 1 MSS and the SNX14 phenotype share the presence of ID, cerebellar atrophy, hypotonia, and ataxia. Therefore SNX14 should be screened in MSS-like individuals not carrying an SIL1 mutation, especially in those without microcephaly, cataracts, or myopathy (creatinine kinase levels were in the normal range for the four individuals tested who have SNX14 mutations). Zheng et al. 44 reported that heterozygous Snx13 þ/À mice do not have an obvious phenotype, whereas Snx13 À/À mice die between E10.5 and E14.5. Mutants are small and have exencephaly and abnormal cephalic vascularization, presumably in response to defective nutrient uptake and transport, particularly in the yolk sac endoderm, which could account for embryonic developmental delay. Snx14 knockdown studies using lentiviral shRNA, specifically in mouse cortical pyramidal neurons, were recently reported. 36 Despite incomplete (60%) knockdown, significantly reduced intrinsic excitability and synaptic function was recorded. The study of Huang et al. 36 also reported Snx14 to be maternally imprinted but suggest that this might be mouse specific. Our data support this because unaffected heterozygous individuals inherit the mutation on either the maternal or paternal allele (Figure 2A ).
In conclusion, in terms of a potential mechanism there is a compelling case for a role of SNX14 in synaptic transmission. 40 Synaptic dysfunction is well known to be impli- Spatio-temporal SNX14 (left) and SNX13 (right) transcriptomes of the human brain using data from the Human Brain Transcriptome (HBT) database. 34 This study assessed 6 brain regions (cerebellar cortex (CBC), mediodorsal nucleus of the thalamus (MD), striatum (STR), amygdale (AMY), hippocampus (HIP) and the neocortex (NCX)) over 15 periods of the human pre and post-natal development. These data were generated from Affymetrix Human Exon 1.0 ST Arrays performed on 1,340 tissue samples collected from 57 developing and adult post-mortem brains of clinically unremarkable donors representing males and females of multiple ethnicities. Levels of SNX14 increase throughout the brain during fetal development, before plateauing. In the cerebellum, expression continues to rise during postnatal life reaching its highest level during adulthood. Contrast with SNX13, which decreases towards birth, then more modestly increases in most brain regions. Bottom: Regional distribution of SNX14 (left) and SNX13 (right) expression in human brain. Box plots of mRNA levels from 10 brain regions (left to right: the cerebellum (CRBL, n=130), frontal cortex (FCTX, n=127), hippocampus (HIPP, n=122), medulla (specifically inferior olivary nucleus, MEDU, n=119), occipital cortex (specifically primary visual cortex, OCTX, n=129), putamen (PUTM, n=129), substantia nigra (SNIG, n=101), temporal cortex (TCTX, n=119), thalamus (THAL, n=124), and intralobular white matter (WHMT, n=131)) are based on microarray experiments and plotted on a log2 scale (yaxis). Material and methods were as previously reported. 34, 35 In brief, these 
